MCOLN2

Across TCGA pan-cancer cohorts, MCOLN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MCOLN2 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MCOLN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCOLN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, STAD, and UCEC are the cancer types where MCOLN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.250	0.541	.028	18	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.025	18	view →
SKCM	DFS	Median	II,III,IV	0.964	0.533	.002	13	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MCOLN2–OV (DFS)

Open the OV breakdown →